Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Neurology and Neurosurgery"
DOI: 10.1016/j.clineuro.2019.04.013
Abstract: Idarucizumab is the first Food and Drugs Administration (FDA) approved reversal agent for anticoagulant dabigatran, a direct thrombin inhibitor. Emerging evidence suggests idarucizumab can improve clinical outcome following dabigatran-associated hemorrhage, however, its specific use in… read more here.
Keywords: literature; intracranial hemorrhage; hemorrhage; idarucizumab setting ... See more keywords
Dabigatran-Associated Thrombocytopenia.
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Therapeutics"
DOI: 10.1097/mjt.0000000000000714
Abstract: function.4,5 To our knowledge, there have been 2 reports of severe neurological dysfunction with ranolazine.4,5 One case of an 81-year-old woman with renal dysfunction (creatinine clearance ,30 mL/min/1.73 m2) experienced neurological symptoms including hallucinations, dysarthria,… read more here.
Keywords: ranolazine; side effects; age; dysfunction ... See more keywords